Name: 3rd Global Conference on Pharma and Pharmaceutical Sciences
Start: 2024-02-22
End: 2024-02-24
Location: Switzerland

Conference Information

Welcome Message

Greetings from Pharma Congress 2024!!

We are glad to invite you all to the"3rd Global Conference on Pharma and Pharmaceutical Sciences which will be held on February 22-23, 2024.

We warmly welcome you all to be a part of our conference as speakers, Attendees, youthful experimenters, to make the conference a successful event. Pharma Congress 2024 is all about conducting the talents of the scholar and showcasing their current research to the world.

We are glad to announce the theme “Exploring the Recent Advancement in Pharmaceutical Science” and aims to bring advanced analysis about pharmaceutical science.

Pharma Congress 2024 includes workshops, symposiums, from speakers who Exceeds in the fields of pharmaceutical science. Pharma Congress 2024 motivates the active participation of young students. Also, we will provide the Poster Award and Young scientists at the meeting.

We are confident that Attendees will be enjoyed and get a wonderful experience.

Zurich, Switzerland will give you a nice view and awesome experience for our meeting.

Why to Attend?

A chance to meet the Expertise by attending the conference 3rd Global Conference on Pharma and Pharmaceutical Sciences will give you the experience about the recent disquisition content.

Speaker will be profitable by getting the benefits like a Certificate from the OCM (Organizing Committee Member) and Abstract publication on Conference Website, Networking openings with global experts, and the occasion to buy conference proceedings hard dupe.

To learn and explore beyond the interest and showcase your ideas in the field of Pharmaceutical science.

And we are also here to notify that there's a network session at the end where you can meet your colleagues and gather information about the current exploration and it'll be a great occasion to make your network.

Sessions and Tracks

Tracks and subtrack:

Track 1: Pharmaceutical Science:

Pharmacology is a medical discipline that evolved from mediaeval apothecaries, who prepared and prescribed drugs. In the early nineteenth century, a schism developed between apothecaries who treated patients and those whose primary interest was in the preparation of medicinal compounds; the latter served as the foundation for the emerging speciality of Pharmacology. Only after advances in chemistry and biology in the late 18th century enabled drugs to be standardised and purified did a truly scientific Pharmacology emerge. By the early nineteenth century, French and German chemists had isolated many active substances from crude plant sources, including morphine, strychnine, atropine, quinine, and many others. Oswald Schmeiderberg, a German, established Pharmacology in the late nineteenth century (1838–1921). He defined its purpose, wrote a Pharmacology textbook, and assisted in its development and helped to found the first pharmacological journal, and most importantly, directed a school in Strasbourg that served as the foundation for independent Pharmacology departments in universities around the world.

· Nano Robotics

· Neuro Pharmacology

· Pharmacogenetics

Track 2: Pharmacodynamics:

The effects or actions of a drug at the molecular, biochemical, and physiologic levels. It is derived from the Greek words "pharmakon," which means "drug," and "dynamikos," which means "power." All drugs exert their effects by interacting at the molecular level with biological structures or targets, causing a change in how the target molecule functions in relation to subsequent intermolecular interactions. Receptor binding, post-receptor effects, and chemical interactions are examples of these interactions. Examples of these interactions include drugs binding to an enzyme's active site, drugs interacting with cell surface signalling proteins to disrupt downstream signalling, and drugs acting through binding molecules such as tumour necrosis factor.

Sub Track:

· Overview of Pharmacodynamics

· Drug–Receptor Interactions

· Effect of Aging on Drug Response

Track 3:

Drug Discovery and Development:

In response, MMV and DNDi, in collaboration with scientists from industry and academia, created the Pandemic Response Box to encourage new research into pandemic disease treatments. The box will contain 400 structurally diverse compounds for screening against infectious and neglected diseases. Disease experts chose these 400 compounds with diverse mechanisms of action from a large list of antibacterial, antiviral, and antifungal compounds. They are all either already on the market or are in various stages of drug discovery or development. The biological activity of the compounds has not been confirmed by MMV/DNDi partners; the choice was made based on information available in the literature.

Sub Track:

· Advanced Pharmaceutics

· Proteomics

· Drug metabolism and toxicology

Track 4: Chemotherapy

Chemotherapy works by killing cells that divide quickly, which is one of the main characteristics of cancer cells. This means that it also harms cells that divide rapidly under normal conditions, such as those in the bone marrow, digestive tract, and hair follicles; this results in the most common side effects of chemotherapy, such as myelosuppression (lower blood cell production), mucositis (inflammation of the digestive tract lining), and alopecia (hair loss). Other applications for cytostatic chemotherapy agents (including those listed below) include the treatment of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis, as well as the prevention of transplant rejection (see immunosuppression and DMARDs)

Sub Tracks:

· Anti-metabolites

· Mitotic inhibitors

· Alkylating agents

Track 5: Pharmacognesy

Modern pharmacognosy incorporates these important new areas into a separate interdisciplinary science. Pharmacognosy's emphasis and focus of study have shifted dramatically from drug identification, such as active constituent isolation, to, more recently, biological activity investigation. Pharmaceutical companies use pharmacognosy to screen, characterise, and produce new drugs for the treatment of human disease. Because naturally occurring drugs are frequently not mass-produced, they must be studied in order to develop synthetic biosimilars. Future developments in pharmacognosy and the herbal drug industry will be heavily reliant on reliable methodologies for identifying marker compounds in extracts, as well as standardisation and quality control of these extracts.

Sub Tracks:

· Microbes

· Alternative Medicine

· Photochemistry

Track 6: Gene Therapy

The use of CRISPR/Cas9 gene editing improves the efficacy of ultrasound cancer therapy. Dec. 8, 2021 — Sonodynamic therapy employs ultrasound in conjunction with drugs to cause harmful reactive oxygen species (ROS) to be released at the site of a tumor. Gene therapy has the potential to treat a wide variety of diseases, including cancer, cystic fibrosis, heart disease, diabetes, haemophilia, and AIDS. Researchers are still investigating when and how to use gene therapy. Gene therapy in Pharmaceutical Science is currently only available in the United States as part of a clinical trial. By 2020, the remission rate for ALL patients treated with Kymriah was expected to be around 85%. After a year, more than half had no relapses. Novartis intends to track the outcomes of all patients who received the therapy for the next 15 years in order to better understand how long it will be effective.

Sub Track:

· Biotechnology

· DNAs and RNAs

· Genetic Disorder

Track 7: Pharmacovigilance

Pharmacovigilance is the science and activities concerned with the detection, assessment, comprehension, and prevention of adverse effects or other medical problems. The European Medicines Agency (EMA) coordinates the pharmacovigilance system in the European Union (EU) and operates services and processes to support pharmacovigilance in the EU.

Before a medicine is approved for use, evidence of its safety and efficacy is limited to clinical trial results, in which patients are carefully selected and closely monitored under controlled conditions. This means that at the time of approval, a medicine had been tested in a relatively small number of carefully selected patients for a limited period of time.

Sub Track:

· Drug Abuse

· Clinical Trials

· Signal Detection

Track 8: Neuropharmacology

Neuropharmacology is the study of drugs that have an effect on the nervous system. Its focus is on the development of compounds that may benefit people suffering from neurological or psychiatric illnesses. Prior to the development of neuropharmacology, there were only four drugs available for nerve disorders: morphine, caffeine, nitrous oxide, and aspirin. Over the next 50 years, a new class of drugs emerged, including antihistamines, barbiturates, and opioid analogues.

With modern insights into the molecular basis of many drugs' actions and the availability of current research methods, work to understand how the brain works at the molecular and cellular levels is ongoing. This includes understanding the role of genetic variation in drug effects and drug delivery to the brain.

Sub Track:

· Autonomic Neuroscience

· Neural Technology

· Neuronal Survival and apoptosis

Track 9: Biopharmaceuticals

Biopharmaceuticals are among modern science's most sophisticated and elegant achievements. These drugs' massive, complex structures not only look incredible in the 3-D modelling systems used to create them; they also perform remarkably well, with high efficacy and few side effects. And there's plenty more to come: existing treatment archetypes are constantly evolving and becoming more sophisticated, while ongoing research is yielding entirely new types of products. The cell therapy Provenge, which is used to treat cancer, and, a little further out, gene therapies, which offer even more amazing promises of regenerative medicine or disease remission, are making their way to the market in Biopharmaceuticals .

Sub Track:

· Vaccines

· Hematology

· Recombinant protein therapy

Track 10: Safety Pharmacology

As part of an IND-enabling programme, safety Pharmacology evaluations are an essential step in assessing acute and potentially life-threatening risks of novel pharmaceuticals. Charles River experts devote time to risk mitigation by evaluating programmes in the discovery/lead optimisation phase, saving time in the preclinical phase of development. Learn from the CRO where 25% of the world's Diplomates in Safety Pharmacology (DSPs) have chosen to pursue a career.

Sub Track:

· Detection of adverse effects liability

· Mitigation strategies

· Implications for clinical safety monitoring

Track 11: Drug Formulation

Pharmaceutical formulation is a multistep process in which the active drug is mixed with all other components while taking particle size, polymorphism, pH, and solubility into account to create the final beneficial medicinal product. The four basic components for a successful pharmaceutical formulation are the benefits and constraints of active pharmaceutical ingredients (APIs), valuable excipients, associated interactions, and manufacturing procedure. The formulation frequently functions in a way that includes multiple dosage forms. The dosage form is the pharmaceutical drug product that has been marketed for use with a specific combination of active and inactive ingredients. It must be in a specific configuration (for example, a capsule shell) and distributed in a specific dose.

Sub Track:

· Chemical Analysis

· Polymorphism

· Genetic Disorder

Track 12: Radiopharmacology

Radiopharmacology is the application of radiochemistry to medicine, and thus the Pharmacology of radiopharmaceuticals (medicinal radio compounds, that is, pharmaceutical drugs that are radioactive). Radiopharmaceuticals are used as radioactive tracers in medical imaging and therapy for a variety of diseases in the field of nuclear medicine (for example, brachytherapy). Many radiopharmaceuticals employ technetium-99m (Tc-99m), a gamma-emitting tracer nuclide with numerous applications. There are 31 different radiopharmaceuticals based on Tc-99m listed in the book Technetium for imaging and functional studies of the brain, myocardium, thyroid, lungs, liver, gallbladder, kidneys, skeleton, blood, and tumours. The term radioisotope, which refers to any radioactive isotope (radionuclide) in its broadest sense, has historically been used to refer to all radiopharmaceuticals, and this usage persists.

Sub Track:

· Molecular Biology

· Ligand Targeting

· Radiation Therapy

Track 13: Clinical Trials:

Clinical trials are research studies in which people are subjected to a medical, surgical, or behavioural intervention. These trials are the primary means by which researchers determine whether a new form of treatment or prevention, such as a new drug, diet, or medical device (such as a pacemaker), is safe and effective in humans. Many consider clinical trials to be the gold standard method for evaluating healthcare interventions, as opposed to observational studies. They make significant contributions to relevant research evidence developed by the NIHR to assist the NHS in England and other care providers. However, clinical trials are complex, and many researchers, particularly those in their early careers, struggle to know where to begin in order to contribute to or lead a trial.

Following the completion of an internal report on trainee engagement in clinical trials, the NIHR Trainees Coordinating Centre launched a project to create a resource for individuals interested in pursuing a research career that includes the delivery of clinical trials.

Sub Track:

· Prevention Trials

· Screening Trials

· Treatment Trials

Target Audience

Professors
Deans
Directors
CEO
Scientists
Lab technician
Health care professionals
Students
Pharmaceutical Nursing & Midwifery Associations
Pharmacology Doctors and Specialists
Pharmaceutical Training Institutes
Pharmaceutical Companies

Mode of Participation

Oral Presentation
Virtual Presentation
Workshop Presentation
Symposium
Poster Presentation

Market Analysis

The Pharmaceutical industry is a multi-billion bone business assigned with researching, developing, manufacturing and distributing medicines for mortal and beast use. The stakes are high; lives and plutocrat are on the line each time a new drug is conceived. And because the process from medicine generality to its delivery is a long one, it’s important that companies do the necessary exploration to ensure that they're meeting a good demand and have the needful tools and information that they need to succeed. else, they risk losing a lot of plutocrats and a lot of time on a product that no one wants or needs. Combine that with the changing geography of the pharma assiduity – this point in time of American medicine history when crucial medicine patents are expiring (generally after a 20-time period) and further and further generics are hitting the request – and it’s easy to understand that pharmaceutical companies must find new medicines, as well as boost declining deals of their established bones, if they want to survive.

The global medicinal manufacturing request size was valued at USD405.52 billion in 2020 and is anticipated to grow at a composite periodic growth rate (CAGR) of11.34 from 2021 to 2028. The pharmaceutical geography has experienced a massive metamorphosis with the emergence of new technologies, cost-effective, and more effective manufacturing approaches. In addition, adding investment inflow in this space has impacted the request growth appreciatively. Manufacturing bottom time-out and the product of product waste are reduced by the perpetration of robotic technology and Artificial Intelligence (AI). In addition, single- use disposable results have gained instigation in this assiduity and have replaced conventional open transfer manufacturing ways. likewise, the paradigm shifts towards integrated, smart, and data-rich paperless operations has redounded in error-free and precise product. similar ongoing developments have propelled medicine manufacturing.

Constant progress in the field of substantiated drugs has opened up multitudinous possibilities to target different health distemperatures and allowed the development of case- centric models. This progress results in a shift from large batches to lower batches for the development of complex drugs and autologous case- centric treatments. This has also encouraged the manufacturers to redesign their force chain to more align with the case- centric health care system.

A rise in medicine blessings by the nonsupervisory bodies is anticipated to fuel the medicine manufacturing procedures. For case, the FDA approved 59 medicines in 2018, 49 medicines in 2019, and 15 medicines up to April 2020. likewise, a large number of ongoing clinical trials have created multitudinous growth openings for request growth. Combinations & accessions in the pharmaceutical assiduity have increased in the once many times. utmost of the well- established companies is consolidating to enhance their request position in the largely competitive terrain. Whereas small- tomid-sized pharma companies are being acquired for their innovative capabilities. also, strict regulations to check pharmaceutical prices have redounded in a large number of combinations & accessions.

3rd Global Conference on
Pharma and Pharmaceutical Sciences

Quick Links

Theme: Exploring the Recent Advancement in Pharmaceutical Science

Conference Information

Welcome Message

Why to Attend?

Sessions and Tracks

Target Audience

Mode of Participation

Market Analysis